Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Total Valuation
Halozyme has a market cap or net worth of $7.44B. The enterprise value is $7.11B.
Market Cap$7.44B
Enterprise Value$7.11B
Share Statistics
Halozyme has 123.53M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding123.53M
Owened by Insiders1.09%
Owened by Instutions23.94%
Financial Efficiency
Halozyme’s return on equity (ROE) is 1.22 and return on invested capital (ROIC) is 22.84%.
Return on Equity (ROE)122.06%
Return on Assets (ROA)21.52%
Return on Invested Capital (ROIC)22.84%
Return on Capital Employed (ROCE)28.66%
Revenue Per Employee$2,900,925.714
Profits Per Employee$1,268,831.429
Employee Count350
Asset Turnover0.49
Inventory Turnover1.12
Valuation Ratios
The current PE Ratio of Halozyme is 13.65. Halozyme’s PEG ratio is 0.21.
PE Ratio13.65
PS Ratio5.97
PB Ratio16.67
Price to Fair Value16.67
Price to FCF12.95
Price to Operating Cash Flow12.66
PEG Ratio0.21
Income Statement
In the last 12 months, Halozyme had revenue of $1.02B and earned $444.09M in profits. Earnings per share was $3.50.
Revenue$1.02B
Gross Profit$820.38M
Operating Income$551.48M
Pretax Income$557.13M
Net Income$444.09M
EBITDA646.55M
Earnings Per Share (EPS)3.50
Cash Flow
In the last 12 months, operating cash flow was $479.06M and capital expenditures -$10.70M, giving a free cash flow of $468.37M billion.
Operating Cash Flow$479.06M
Free Cash Flow$468.37M
Free Cash Flow per Share$3.79
Dividends & Yields
Halozyme pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield7.72%
Earnings Yield7.32%
Stock Price Statistics
Beta0.92
52-Week Price Change55.53%
50-Day Moving Average60.08
200-Day Moving Average55.67
Relative Strength Index (RSI)50.64
Average Volume (3m)1.68M
Important Dates
Halozyme upcoming earnings date is May 13, 2025, After Close.
Last Earnings DateFeb 18, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Halozyme as a current ratio of 7.80, with Debt / Equity ratio of 4.14
Current Ratio7.80
Quick Ratio6.78
Debt to Market Cap0.25
Net Debt to EBITDA2.12
Interest Coverage Ratio30.48
Taxes
In the past 12 months, Halozyme has paid $113.04M in taxes.
Income Tax$113.04M
Effective Tax Rate20.29%
Enterprise Valuation
Halozyme EV to EBITDA ratio is 11.35, with an EV/FCF ratio of 15.91.
EV to Sales7.34
EV to EBITDA11.35
EV to Free Cash Flow15.91
EV to Operating Cash Flow15.56
Balance Sheet
Halozyme has $596.07M in cash and marketable securities with $1.51B in debt, giving a net cash position of $909.72M billion.
Cash & Marketable Securities$596.07M
Total Debt$1.51B
Net Cash$909.72M
Net Cash Per Share$7.36
Tangible Book Value Per Share-$3.59
Margins
Gross margin is 84.30%, with operating margin of 54.32%, and net profit margin of 43.74%.
Gross Margin84.30%
Operating Margin54.32%
Pretax Margin54.87%
Net Profit Margin43.74%
EBITDA Margin64.66%
EBIT Margin56.65%
Analyst Forecast
The average price target for Halozyme is $67.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$67.50
Price Target Upside12.09%
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast22.44%
EPS Growth Forecast63.47%